Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 orelabrutinib versus placebo in primary progressive multiple sclerosis
NL-OMON61157Phase 3Not yet recruiting
- Sponsor
- Zenas BioPharma
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in primary progressive multiple sclerosis (PPMS), sponsored by Zenas BioPharma. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON61157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61157.